Sai Parenteral's (NSE:SAIPARENT) Research & Development: ₹0 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAIPARENT Sai Parenteral's Ltd NSE:SAIPARENT
14 GF Score
Price ₹569.70
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Research & Development?

Sai Parenteral's NSE:SAIPARENT +5.28% 14 Research & Development is ₹0 Mil as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sai Parenteral's's Research & Development for the six months ended in Sep. 2025 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0 Mil.

Sai Parenteral's  (NSE:SAIPARENT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sai Parenteral's Research & Development Related Terms

Sai Parenteral's Research & Development Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Research & Development Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Research & Development
0.00 0.00 0.00

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Research & Development 0.00 0.00 0.00 0.00
NSE:SAIPARENT
14GF Score
Sai Parenteral's Ltd NSE:SAIPARENT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Research & Development of ₹0 Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on Sai Parenteral's and its competitors.
Is Sai Parenteral's' Research & Development too high?
Sai Parenteral's' current Research & Development is ₹0 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Research & Development compare to LLY and JNJ?
Sai Parenteral's' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Research & Development is ₹0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges 544742:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for NSE:SAIPARENT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹569.70
Price